Published January 16, 2015 | Version v1
Journal article Open

Micro-implant d'acétonide de fluocinolone (ILUVIEN(®)) pour l'œdème maculaire diabétique chronique. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]

Description

Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN(®), which is a new sustained-release, non biodegradable, injectable, intravitreal micro-implant containing fluocinolone acetonide. The results of the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) studies, conducted to evaluate the efficacy and safety of ILUVIEN(®) in DME, are discussed.

Files

25601517_Postprint.pdf

Files (1.0 MB)

Name Size Download all
md5:65c3234027dc490e0ddb00a7db7e390f
1.0 MB Preview Download

Additional details

Related works

Is referenced by
25601517 (PMID)